Chymotrypsin API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Chymotrypsin API 9004-07-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Chymotrypsin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Chymotrypsin
- Synonyms:
- alpha-Chymotrypsin A , Chymotrypsin B , Chymotrypsine , Chymotrypsinum , Quimotripsina
- Cas Number:
- 9004-07-3
- DrugBank number:
- DB09375
- Unique Ingredient Identifier:
- BVS505O332
General Description:
Chymotrypsin, identified by CAS number 9004-07-3, is a notable compound with significant therapeutic applications. Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and polypeptides. It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. Like most proteolytic enzymes, chymotrypsin is activated from its inactive zymogen precursor, chymotrypsinogen, in presence of . Chymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein synthesized by the exocrine pancreas . Chymotrypsin contains both the catalytic triad and oxyanion hole, and the tertiary structure of chymotrypsin is similar to .
Indications:
This drug is primarily indicated for: No therapeutic indications. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Chymotrypsin undergoes metabolic processing primarily in: No pharmacokinetic data available. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Chymotrypsin are crucial for its therapeutic efficacy: No pharmacokinetic data available. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Chymotrypsin is an important consideration for its dosing schedule: No pharmacokinetic data available. This determines the duration of action and helps in formulating effective dosing regimens.
Protein Binding:
Chymotrypsin exhibits a strong affinity for binding with plasma proteins: No pharmacokinetic data available. This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Chymotrypsin from the body primarily occurs through: No pharmacokinetic data available. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Chymotrypsin is distributed throughout the body with a volume of distribution of: No pharmacokinetic data available. This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Chymotrypsin is a critical factor in determining its safe and effective dosage: No pharmacokinetic data available. It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Chymotrypsin exerts its therapeutic effects through: Chymotrypsin is a digestive enzyme synthesized in the pancreas that plays an essential role in proteolysis, or the breakdown of proteins and polypeptides. As a component in the pancreatic juice, chymotrypsin aids in the digestion of proteins in the duodenum by preferentially cleaving peptide amide bonds. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Chymotrypsin functions by: Chymotrypsin is synthesized by pancreatic acinar cells as an inactive precursor, chymotrypsinogen, that is secreted to the duodenum and activated via trypsin-induced cleavage. It also induces its own activation by cleaving essential amino acid residues in the oxyanion hole to produce α-Chymotrypsin, which is a more stable form than π-Chymotrypsin. Residues His-57, Asp-102, and Ser-195 form the catalytic triad while residues 189–195, 214–220, and 225–228 form the primary substrate-binding pocket called S1 binding pocket . Residue 189 in the polar serine residue that lies at the bottom of the S1 binding pocket . Chymotrypsin favors aromatic residues like phenylalanine, tyrosine, and tryptophan but may hydrolyze other bonds in peptides at slower rates. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Categories:
Chymotrypsin is categorized under the following therapeutic classes: Blood and Blood Forming Organs, Endopeptidases, Enzymes, Enzymes and Coenzymes, Hydrolases, Ophthalmologicals, Peptide Hydrolases, Sensory Organs, Serine Endopeptidases, Serine Proteases, Surgical Aids. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Chymotrypsin is a type of Hematological Agents
Hematological agents, belonging to the pharmaceutical API category, are a vital class of drugs used in the treatment of various blood disorders and hematological conditions. These agents play a crucial role in managing diseases related to the blood and its components, such as red blood cells, white blood cells, platelets, and plasma.
One significant application of hematological agents is in the treatment of anemia, a condition characterized by a low red blood cell count or hemoglobin level. Hematopoietic growth factors, a subclass of hematological agents, stimulate the production of red blood cells and enhance their maturation, thereby addressing anemia.
Another area where hematological agents demonstrate their therapeutic potential is in the treatment of blood cancers, such as leukemia, lymphoma, and multiple myeloma. These agents, including chemotherapy drugs and targeted therapies, help suppress the abnormal growth of cancer cells and restore normal blood cell production.
Hematological agents also find application in managing bleeding disorders, such as hemophilia and thrombocytopenia. They work by promoting blood clotting and preventing excessive bleeding. Additionally, certain hematological agents function as immunosuppressants, playing a crucial role in hematopoietic stem cell transplantation and preventing graft-versus-host disease.
Overall, hematological agents form a vital category within the pharmaceutical API domain, offering targeted treatments for a range of blood disorders and playing a significant role in improving the quality of life for patients with hematological conditions.